Endosense and Siemens Healthcare work together in development project to improve electrophysiology ablation procedures

171

Endosense and Siemens Healthcare have agreed to commence a joint development project intended to integrate the contact-force data provided by Endosense’s TactiCath force-sensing ablation catheter with Siemens’ electrophysiology solutions. The goal is to develop a technologically advanced, all-in-one software application that allows electrophysiologists to visualise catheter-tip-to-tissue contact force within a three-dimensional anatomic heart model during catheter ablation procedures.

“The joint development project between Endosense and Siemens represents a very promising area of future advancement in the field of catheter ablation, as it will offer electrophysiologists a new platform for incorporating contact force sensing into clinical practice,” said Eric Le Royer, chief executive officer, Endosense.

“We believe optimisation of catheter tip-to-tissue contact force bears huge potential to improve effectiveness and efficiency of electrophysiology ablation procedures. However, it is important to visualise this new parameter in relation to the 3D anatomy of the heart and, if available, planning data,” said Martin Ostermeier, director of Innovations of the Interventional X-ray business unit of Siemens Healthcare. “The goal of our joint project is to demonstrate the clinical benefits of Endosense’s TactiCath technology integrated into the advanced 3D imaging capabilities, the syngo DynaCT cardiac of our Artis zee family of cath-lab angiography systems for EP procedures.”

Endosense’s TactiCath1 force-sensing ablation catheter and TactiSys system pioneered the field of contact force sensing in catheter ablation. Launched in April 2010, the second generation device is now used by electrophysiologists across Europe for the treatment of atrial fibrillation and supraventricular tachycardia. A growing body of evidence has reinforced the value of force sensing in improving patient outcomes of catheter ablation procedures. Endosense is building upon this data with its recently launched TOCCASTAR investigational device exemption (IDE) study.

(Visited 47 times, 1 visits today)